Landmark Publication Endorses Prana's Drug Pipeline Strategy for Treating Neurodegenerative Diseases
Prana Biotechnology (NASDAQ: PRAN) today announced that the Journal of Biological Chemistry* has published research that provides strong validation of Prana's strategy to treat neurodegenerative diseases.
The authors, led by Professor Susan Lindquist, Professor of Biology at Massachusetts Institute of Technology, discussed the broad therapeutic potential of 8-hydroxyquinolines (8-OHQ), which were identified as being protective against the neurotoxic proteins that cause disease in disorders such as Alzheimer's, Huntington's, Parkinson's and other neurodegenerative disorders. PBT2, Prana's lead Phase II drug is a specific type of 8-OHQ designed and selected for enhanced efficacy and tolerability as a therapeutic intervention. The authors cite the positive therapeutic results of PBT2.
The paper, titled "Different 8-OHQ's Protect Models of TDP-43, alpha-synuclein, and Polyglutamine Proteotoxicity through Distinct Mechanisms," describes the identification of selected 8-OHQ compounds, from 200,000 compounds tested, as protective against neurodegeneration due to their influence on metal homeostasis in the brain. The authors noted that the "ability of different 8-OHQ's to impinge on diverse proteotoxicities (neurotoxicity caused by overabundant mutant or misfolded proteins) further links metal homeostasis to neurodegenerative diseases including Alzheimer's, Parkinson's and Huntington's diseases."
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.